Wedbush Rates Zura Bio (ZURA) buy, $15 Price Target
Wedbush remains bullish on ZURA, maintaining its buy rating with a price target of $15, a 172.73% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated Zura Bio Limited ($ZURA) "buy" with a $15 price target on July 1, 2026.
Since the rating, $ZURA is up 9.8% after 1 week, up 8.6% after 1 month and down 22.4% to date (from the $5 close on Jul 1, 2026).
ZURA
Zura Bio Limited
Key Points
- Wedbush reiterated its buy rating on ZURA with a $15 price target on July 1, 2026.
- Wedbush's $15 price target implies 172.73% upside from Zura Bio Limited's ($ZURA) current $5.50 share price.
- ZURA shares traded near $5.50 on Wednesday with insider buying activity noted on June 17, 2026.
- Suvrettra Capital and Venrock Adviser increased their ZURA holdings significantly in recent filings.
Get $ZURA trade alerts by text
We text you when insiders, Congress or big funds trade $ZURA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zura Bio Limited alert may contain errors. Disclosures
On July 1, 2026, Wedbush reaffirmed its buy rating on ZURA, setting a price target of $15. Analyst Martin Fan from Wedbush believes in the stock's potential, maintaining a bullish stance without altering the target price.
Wedbush vs. the S&P 500
Hypothetical returns from Wedbush's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in ZURA
Suvrettra Capital Management, LLC increased its holdings in ZURA by 3.5 million shares, resulting in a total of about 9.1 million shares valued at approximately $53.9 million, a 62.9% increase. Venrock Adviser, LLC also boosted its stake by 1,089,875 shares, holding about 6.4 million shares worth $38.3 million, marking a 20.4% increase. Meanwhile, JPMorgan Chase & Co slightly trimmed its position by 13,905 shares, maintaining around 4.5 million shares valued at $25.3 million. Great Point Partners LLC added 400,000 shares, bringing its total to 4.2 million shares worth $25.1 million, reflecting a 10.5% increase. Siren, L.L.C. notably grew its position by 2,434,866 shares, totaling about 3.7 million shares valued at $22.2 million, a significant 187.3% increase.
Zura Bio Limited Stock Up 23.3%
Shares of ZURA traded near $5.50 on Wednesday. Despite the recent analyst activity, the stock has shown varied movements, with institutional investors making notable changes to their portfolios. The stock's performance continues to attract attention from both analysts and investors.
$ZURA price target
Zura Bio Limited daily closes and this analyst's $15 target. Not advice.
Insider Buying and Selling at Zura Bio Limited
On June 17, 2026, several insiders including Steven Schoch, Mark Eisner, Daniel Becker, Jennifer Jarrett, Amit Munshi, and Parvinder Thiara each bought 51,000 shares of ZURA. These transactions were not part of any pre-planned trading programs, indicating a strong belief in the company's future prospects.
Analysts Set New Price Targets
On July 1, 2026, Wedbush reiterated its buy rating on ZURA with a $15 price target. Earlier, on March 23, 2026, Chardan Capital maintained its buy rating with an $11 target, and on March 20, 2026, Oppenheimer also kept a buy rating with a $15 target. The consensus among analysts remains positive, with most maintaining a buy recommendation.
Bottom Line
Wedbush's reaffirmation of a buy rating on ZURA with a $15 target highlights continued confidence in the company's potential. The stock's recent trading activity and insider buying suggest that both institutional and individual investors are keeping a close eye on ZURA's performance. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect current market conditions.
Related Filing Alerts
Source: Wedbush's rating change on $ZURA (Jul 1, 2026). Written by software, not financial advice. How we make alerts